Prøve GULL - Gratis

Countering Obesity with Drugs Vs Viable Alternatives

Bio Spectrum

|

BioSpectrum India June 2025

A sizable obese population in India is a free ground for multinational pharma companies to launch various anti-obesity drugs.

Countering Obesity with Drugs Vs Viable Alternatives

Let aside the affordability issue, these drugs can be a game changer. However, severe side effects lurk in the background. Alternative treatment and fundamental lifestyle changes can be seen as an alternative mode to counter obesity. Let's examine the available and prospective obesity therapeutics.

The current state of obesity in India is alarming. As was evident from Prime Minister Narendra Modi's 119th Maan Ki Baat, where he cautioned against the rise in obesity cases that have doubled in the last few years. A major concern during his speech was how children are getting affected more. Union Minister Dr Jitendra Singh, a renowned Diabetologist, also raised alarms while underscoring the urgent need for a multifaceted and collective approach to combat the growing obesity crisis in India.

India's stint with obesity started in the last 20th century with people getting addicted to sugary drinks, junk foods etc. Rapid urbanisation, economic development, lifestyle changes and less physical activity all contributed to a rise in the obese population. Obesity is linked with stigma, and many encounter fat shaming. It leads to psychological stress. This apart, an obese person is vulnerable to various health issues like heart disease, type 2 diabetes, high blood pressure, cancer, sleep apnea, etc.

Launch of anti-obesity drugs

Seeing this as a strategy to market anti-obesity drugs, many multinational pharmaceutical companies are in a rat race to launch various products. With the launch of weight-loss drugs in the Indian market, the debate around pharmacological obesity treatment has intensified.

Seeking an opportunity, the US pharma major, Eli Lilly, recently launched Mounjaro. It is a single-dose vial presentation and has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO). The company went ahead and also launched a campaign to combat the associated stigma with obesity.

FLERE HISTORIER FRA Bio Spectrum

Bio Spectrum

Bio Spectrum

Molbio announces collaboration with UE LifeSciences to expand iBreastExam globally

Molbio Diagnostics, a Goa-based point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies, and UE LifeSciences, a Philadelphia-based innovator engaged in the business of developing and manufacturing health technology solutions, with a primary focus on enabling early cancer detection technologies, have announced an exclusive collaboration, seeking to make early breast cancer detection accessible to millions of women in over 50 countries across the developing world.

time to read

1 min

November 2025

Bio Spectrum

Bio Spectrum

CRO Reforms: Tilting Scale towards Accelerated Growth & Transparency

India's clinical research ecosystem is undergoing a major transformation, driven by a wave of regulatory reforms and rapid market expansion.

time to read

10 mins

November 2025

Bio Spectrum

When Spectra Speak: Letting AI Read the Fine Print of Biologics

Biologic characterisation has historically relied heavily on spectroscopy, which transforms chemical complexity into comprehensible fingerprints. Through the careful use of AI, supported by strict data procedures and scientific supervision, these fingerprints may be read more quickly & thoroughly.

time to read

5 mins

November 2025

Bio Spectrum

Working on our supply chain to set benchmarks in quality and further enhance India's position as a trusted clinical research supplier on a global scale

Abdos Lifesciences, which is committed to enabling science to thrive by delivering precision-engineered, high-performance laboratory consumables and instruments that meet the highest global standards, manufactures over 400 products across 12+ categories in automated cleanroom environments certified under ISO and CE-IVDR standards, ensuring sterility, traceability, and consistency crucial for decentralised and global clinical trials. Each product is barcoded, tamper-proof, and supported by easily accessible documentation such as Certificates of Analysis (COA), Technical Data Sheets (TDS). With a presence in more than 90 countries, Abdos Lifesciences ensures researchers worldwide receive reliable products and dedicated support, empowering science to advance seamlessly across borders and timelines. In an interview with BioSpectrum India Shrey Agarwal, CEO & Director, Abdos Lifesciences spoke to many issues including how the company is ensuring compliance with evolving global standards for products used in regulated clinical environments. Edited excerpts;

time to read

4 mins

November 2025

Bio Spectrum

Gene Solutions and AMPATH launch advanced genomics laboratory in Hyderabad

Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnostic services in India, to open a new advanced genomics laboratory in Hyderabad.

time to read

1 min

November 2025

Bio Spectrum

Patient Consent - How is it different under medical ethics and data protection?

In the ethical and legal framework of medicine and law, consent has always existed. Within healthcare, it signifies the individual's right to be informed and to choose. However, in the digital era, consent assumes a broader function; it becomes the foundation for lawful processing of personal data. For the pharma and clinical-research sectors, this distinction carries significant implications. The Digital Personal Data Protection Act, 2023 (DPDPA), has redefined how personal and health-related data must be managed. This article explores why consent under data-protection law differs from medical consent, drawing lessons from the irregularities uncovered in the Ahmedabad clinical trials, and outlines the emerging compliance responsibilities under the DPDPA.

time to read

3 mins

November 2025

Bio Spectrum

Bio Spectrum

We aim to make bio-based industries a key pillar of the state's GSDP by 2030: Kerala CM

Kerala recently set the spotlight on its growing life sciences ecosystem with Bio Connect 3.0 – International Life Sciences Conclave & Expo, held on October 9 & 10, 2025, in Thiruvananthapuram.

time to read

3 mins

November 2025

Bio Spectrum

Bio Spectrum

DBT inks pact with Uttar Pradesh to boost biotech, pharma and medtech innovation

An official Memorandum of Understanding (MoU) has been signed between the Department of Biotechnology (DBT), Government of India and the Government of Uttar Pradesh.

time to read

1 min

November 2025

Bio Spectrum

Bio Spectrum

Abbott launches world's first dual-chamber leadless pacemaker system in India

Abbott, a global healthcare company, has announced the launch of AVEIR dual chamber (DR) leadless pacemaker system - the first of its kind in the world.

time to read

1 min

November 2025

Bio Spectrum

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

Delhi-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

November 2025

Listen

Translate

Share

-
+

Change font size